Your search for: 'author:("Bråthen, Geir")' has returned 10 results. (0.027s) Save search

Authors: Kvello-Alme, Marte | Bråthen, Geir | White, Linda R. | Sando, Sigrid Botne

Article Type: Research Article

Abstract: Background: The epidemiology of young onset dementia is little researched compared to late onset dementia. Information on incidence rates is vital for medical professionals, and for government planning purposes. Objective: To determine the incidence of young onset dementia in a defined catchment area of central Norway. Methods: The target area was Trøndelag county in central Norway with a total population of 449,796 inhabitants per January 1, 2016. We applied multiple case ascertainment strategies with sources from both primary and secondary healthcare facilities. Included patients received a diagnosis of dementia according to DSM-IV in the ages 30 to 64 years during …the years 2015–2017. Subtypes of dementia were diagnosed according to standardized criteria. Incidence rates for dementia and Alzheimer’s disease with dementia were calculated according to age and sex. Results: A total of 89 incident cases were included. Incidence rates for dementia were 14.8 and 25.0 per 100,000 person-years for the age range 30–64 and 45–64, respectively. Corresponding incidence rates for Alzheimer’s disease were 6.7 and 11.8. Alzheimer’s disease represented half of all dementias. A majority of patients above the age of 50 had neurodegenerative disease, whereas non-degenerative disorders were more prevalent in younger patients. Conclusion: Young onset dementia is a significant contributor to the overall occurrence of dementia in central Norway, and Alzheimer’s disease is by far the most common diagnosis. Show more

Keywords: Alzheimer’s disease, early onset dementia, epidemiology, frequency, incidence, occurrence, young onset dementia

DOI: 10.3233/JAD-191307

Citation: Journal of Alzheimer's Disease, vol. 75, no. 3, pp. 697-704, 2020

Authors: Kvello-Alme, Marte | Bråthen, Geir | White, Linda R. | Sando, Sigrid Botne

Article Type: Research Article

Abstract: Background: Young onset dementia poses several challenges for the individual, health care, and society that are not normally relevant for late onset dementia, but is little researched. Objective: To determine the prevalence and subtypes of young onset dementia in a defined catchment area in central Norway. Methods: The main sources of patient identification were the databases at the Department of Neurology, University Hospital of Trondheim (St. Olav’s Hospital), and Department of Psychiatry, Levanger Hospital. Both departments are the main sites for referral of young onset dementia (onset before age 65 years) in the county, covering approximately 90% of the catchment …area of the study. Other sources included key persons in the communities, collaborating hospital departments examining dementia, and review of hospital records of all three hospitals in the area. Included patients met the DSM-IV criteria for dementia. The prevalence of dementias was calculated by sex and age. Results: All patients identified with dementia and onset before 65 years on census date were included in the study (n  = 390). Patients younger than 65 on census date were included in the calculation of prevalence, giving a result of 76.3 per 100 000 persons at risk in the age category of 30–65 years, and 163.1 per 100,000 for the category 45–64 years. Etiology was heterogeneous, but the main subtype of dementia was Alzheimer’s disease. Conclusions: Young onset dementia affects a significant number of people in central Norway. Prevalence figures are higher than previously reported from England and Japan, but are similar to a more recent study from Australia. Show more

Keywords: Alzheimer’s disease, early onset dementia, epidemiology, prevalence

DOI: 10.3233/JAD-181223

Citation: Journal of Alzheimer's Disease, vol. 69, no. 2, pp. 479-487, 2019

Authors: Kvello-Alme, Marte | Bråthen, Geir | White, Linda R. | Sando, Sigrid Botne

Article Type: Research Article

Abstract: Background: Young onset dementia is associated with a longer time to diagnosis compared to late onset dementia. Earlier publications have indicated that atypical presentation is a key contributing factor to the diagnostic delay. Our hypothesis was that even the most common presentation of Alzheimer’s disease is associated with a substantial diagnostic delay in patients < 65 years. Objective: To determine the time to diagnosis, and time lags in the diagnostic pathway in typical young onset Alzheimer’s disease in central Norway. Methods: The main sources of patients were the databases at the Department of Neurology, University Hospital of Trondheim (St. Olav’s Hospital), and …Department of Psychiatry, Levanger Hospital. Other sources included key persons in the communities, collaborating hospital departments examining patients with suspected cognitive impairment, and review of hospital records of all three hospitals in the area. Information on the time lags, and the clinical assessment, including the use of biomarkers, was collected from hospital notes. Caregivers were interviewed by telephone. Results: Time from first symptom to diagnosis in typical young onset Alzheimer’s disease was 5.5 years (n  = 223, SD 2.8). Time from onset to contact with healthcare services (usually a general practitioner) was 3.4 years (SD 2.3). Time from contact with healthcare services to the first visit at a hospital was 10.3 months (SD 15.5). Time from first visit at a hospital to diagnosis was 14.8 months (SD 22.6). The analysis of cerebrospinal fluid core biomarkers was performed after 8.3 months (SD 20.9). Conclusion: Typical Alzheimer’s disease is associated with a substantial diagnostic delay in younger patients. Raising public awareness, and education of healthcare professionals on the aspects of young onset Alzheimer’s disease is warranted. CSF core biomarkers should be performed earlier in the hospital evaluation process. Show more

Keywords: Clinical characteristics, delayed diagnosis, diagnosis, early onset Alzheimer’s disease, early onset dementia, young onset dementia

DOI: 10.3233/JAD-210090

Citation: Journal of Alzheimer's Disease, vol. 82, no. 3, pp. 965-974, 2021

Authors: Grøntvedt, Gøril Rolfseng | Lauridsen, Camilla | Berge, Guro | White, Linda R. | Salvesen, Øyvind | Bråthen, Geir | Sando, Sigrid Botne

Article Type: Research Article

Abstract: Background: The unbiased amyloid, tau, and neurodegeneration (A/T/N) classification is designed to characterize individuals in the Alzheimer continuum and is currently little explored in clinical cohorts. Objective: A retrospective comparison of the A/T/N classification system with the results of a two-year clinical study, with extended follow-up up to 10 years after inclusion. Methods: Patients (n  = 102) clinically diagnosed as Alzheimer’s disease (AD) with dementia or amnestic mild cognitive impairment (MCI), and 61 cognitively healthy control individuals were included. Baseline cerebrospinal fluid core biomarkers for AD (Aβ42 , phosphorylated tau, and total tau) were applied to the A/T/N classification using the …final clinical diagnosis at extended follow-up as the gold standard. Results: A + T + N+ was a strong predictor for AD dementia, even among cognitively healthy individuals. Amnestic MCI was heterogenous, considering both clinical outcome and distribution within A/T/N. Some individuals with amnestic MCI progressed to clinical AD dementia within all four major A/T/N groups. The highest proportion of progression was among triple positive cases, but progression was also common in individuals with suspected non-Alzheimer pathophysiology (A-T + N+), and those with triple negative status. A-T-N- individuals who were cognitively healthy overwhelmingly remained cognitively intact over time, but in amnestic MCI the clinical outcome was heterogenous, including AD dementia, other dementias, and recovery. Conclusion: The A/T/N framework accentuates biomarkers over clinical status. However, when selecting individuals for research, a combination of the two may be necessary since the prognostic value of the A/T/N framework depends on clinical status. Show more

Keywords: Alzheimer’s disease, amyloid, biomarkers, cerebrospinal fluid, classification, mild cognitive impairment, tau

DOI: 10.3233/JAD-191227

Citation: Journal of Alzheimer's Disease, vol. 74, no. 3, pp. 829-837, 2020

Authors: Kirsebom, Bjørn-Eivind | Espenes, Ragna | Waterloo, Knut | Hessen, Erik | Johnsen, Stein Harald | Bråthen, Geir | Aarsland, Dag | Fladby, Tormod

Article Type: Research Article

Abstract: Background: Cognitive assessment is essential in tracking disease progression in AD. Presently, cohorts including preclinical at-risk participants are recruited by different means, which may bias cognitive and clinical features. We compared recruitment strategies to levels of cognitive functioning. Objective: We investigate recruitment source biases in self-referred and memory clinic-referred patient cohorts to reveal potential differences in cognitive performance and demographics among at-risk participants. Methods: We included 431 participants 40–80 years old. Participants were classified as controls (n  = 132) or symptom group (n  = 299). The symptom group comprised of subjective cognitive decline (SCD, n  = 163) and mild cognitive impairment (MCI, n … = 136). We compared cognitive performance and demographics in memory clinic-referrals (n  = 86) to self-referred participants responding to advertisements and news bulletins (n  = 179). Participants recruited by other means were excluded from analysis (n  = 34). Results: At symptom group level, we found significant reductions in cognitive performance in memory clinic-referrals compared to self-referrals. However, here reductions were only found within the MCI group. We found no differences in cognitive performance due to recruitment within the SCD group. The MCI group was significantly impaired compared to controls on all measures. Significant reductions in learning, and executive functions were also found for the SCD group. Conclusion: Regardless of recruitment method, both the SCD and MCI groups showed reductions in cognitive performance compared to controls. We found differences in cognitive impairment for memory clinic-referrals compared to self-referrals only within the MCI group, SCD-cases being equally affected irrespective of referral type. Show more

Keywords: Alzheimer’s disease, cognitive dysfunction, mild cognitive impairment, patient recruitment, research subject recruitment, sampling studies, subjective cognitive decline

DOI: 10.3233/JAD-170385

Citation: Journal of Alzheimer's Disease, vol. 60, no. 4, pp. 1621-1631, 2017

Authors: Hessen, Erik | Kirsebom, Bjørn-Eivind | Eriksson, Cecilia Magdalena | Eliassen, Carl Fredrik | Nakling, Arne Exner | Bråthen, Geir | Waterloo, Knut K. | Aarsland, Dag | Fladby, Tormod

Article Type: Research Article

Abstract: Background: In the care of persons with cognitive problems, it is important to use a valid mild cognitive impairment (MCI) criterion that discriminates well between normal and pathological aging. Objective: To find the brief neuropsychological screening criterion that best correlates with cerebrospinal fluid (CSF) biomarkers for cognitive decline and dementia in persons seeking help for cognitive problems. Methods: 452 consecutively recruited patients (age 40–80 years) from memory-clinics in the Norwegian national multicentre longitudinal study Dementia Disease Initiation were included. CSF data as well as full data from brief neuropsychological screening were available for all patients. Results: Amnestic MCI, including at …least one memory test below T-score 40, outperformed the conventional US National Institute on Aging-Alzheimer’s Association (NIA-AA) MCI criterion. Only amnestic MCI was significantly associated with biomarker pattern of NIA-AA stage 2 (low CSF Aβ 42 concentrations and elevated tau) in multivariate regression analysis. Conclusions: The finding that amnestic MCI based on brief neuropsychological assessment is significantly associated with CSF biomarkers for cognitive decline and Alzheimer’s disease is in accordance with longitudinal studies that find memory impairment; both in itself and especially in combination with other cognitive deficit to constitute a risk factor for subsequent cognitive decline and dementia. The prevalence of pathological biomarkers for Alzheimer’s disease is common in the elderly and the clinical significance of present findings depend on longitudinal validation. Show more

Keywords: Alzheimer’s disease, amnestic MCI, brief neuropsychological assessment, cerebrospinal fluid biomarkers, mild cognitive impairment, NIA-AA MCI criterion, NIA-AA stage 2

DOI: 10.3233/JAD-180964

Citation: Journal of Alzheimer's Disease, vol. 67, no. 2, pp. 715-723, 2019

Authors: Patra, Kalicharan | Giannisis, Andreas | Edlund, Anna K. | Sando, Sigrid Botne | Lauridsen, Camilla | Berge, Guro | Grøntvedt, Gøril Rolfseng | Bråthen, Geir | White, Linda R. | Nielsen, Henrietta M.

Article Type: Research Article

Abstract: The APOE ɛ 4 gene variant is the strongest genetic risk factor for Alzheimer’s disease (AD), whereas APOE ɛ 3 conventionally is considered as ‘risk neutral’ although APOE ɛ 3-carriers also develop AD. Previous studies have shown that the apolipoprotein E3 (apoE3) isoform occurs as monomers, homodimers and heterodimers with apolipoprotein A-II in human body fluids and brain tissue, but the relevance of a plasma apoE3 monomer/dimer profile to AD is unknown. Here we assessed the distribution of monomers, homodimers and heterodimers in plasma from control subjects and patients with mild cognitive impairment (MCI) and AD with either a homozygous …APOE ɛ 3 (n  = 31 control subjects, and n  = 14 MCI versus n  = 5 AD patients) or APOE ɛ 4 genotype (n  = 1 control subject, n  = 21 MCI and n  = 7 AD patients). Total plasma apoE levels were lower in APOE ɛ 4-carriers and overall correlated significantly to CSF Aβ42 , p(Thr181)-tau and t-tau levels. Apolipoprotein E dimers were only observed in the APOE ɛ 3-carriers and associated with total plasma apoE levels, negatively correlated to apoE monomers, but were unrelated to plasma homocysteine levels. Importantly, the APOE ɛ 3-carrying AD patients versus controls exhibited a significant decrease in apoE homodimers (17.8±9.6% versus 26.7±6.3%, p  = 0.025) paralleled by an increase in apoE monomers (67.8±18.3% versus 48.5±11.2%, p  = 0.008). In the controls, apoE monomers and heterodimers were significantly associated with plasma triglycerides; the apoE heterodimers were also associated with levels of high-density lipoprotein cholesterol. The physiological relevance of apoE dimer formation needs to be further investigated, though the distribution of apoE in monomers and dimers appears to be of relevance to AD in APOE ɛ 3 subjects. Show more

Keywords: Alzheimer’s disease, apolipoprotein A-II, apolipoprotein E, biomarkers, dementia, dimers

DOI: 10.3233/JAD-190175

Citation: Journal of Alzheimer's Disease, vol. 71, no. 4, pp. 1217-1231, 2019

Authors: Berge, Guro | Lauridsen, Camilla | Sando, Sigrid Botne | Holder, Daniel Joseph | Møller, Ina | Aasly, Jan Olav | Bråthen, Geir | Savage, Mary Josephine | White, Linda Rosemary

Article Type: Research Article

Abstract: Background: There is substantial variation caused by preanalytical procedures in the measurement of cerebrospinal fluid (CSF) biomarkers for Alzheimer’s disease (AD) reported in the literature. Objective: Determine whether the detergent Tween-20 improves diagnostic accuracy. Methods: CSF proteins (Aβ42 , Aβ40 , total tau, and phosphorylated tau) were measured by standard ELISA, in uncentrifuged CSF with or without 0.05% Tween-20 from patients with AD or amnestic mild cognitive impairment, and healthy elderly controls. In the main study, collection tubes containing Tween-20 (Sarstedt 15 mL) were filled with 5 mL CSF to ensure consistent detergent concentration across subsequent aliquots into Corning 2 mL tubes. These …latter were also the primary collection vessel for samples without Tween-20. The effect of centrifugation, and extra tube transfer of samples with Tween-20 were also examined. Results: 0.05% Tween-20 significantly increased mean measured CSF concentration of Aβ42 (30% ), Aβ40 (23% ), and total tau (4% ), but not phosphorylated tau. Generally, these increases were similar in all groups, although for Aβ42 , the mean percentage increase with Tween-20 was slightly larger for AD. Areas under receiver-operator characteristic curves were similar whether Tween-20 was present or not. Centrifuged CSF without Tween-20 significantly reduced the measured concentration of Aβ42 versus non-centrifuged samples, a difference not seen when detergent was added. Similar CSF Aβ42 levels were found whether Tween-20 was added at collection in an extra tube or directly to the main collection tube. Conclusion: Addition of Tween-20 to CSF did not improve differentiation of patients from controls. Show more

Keywords: Amyloid beta-peptides, dementia, human, synthetic detergent, tau protein

DOI: 10.3233/JAD-150234

Citation: Journal of Alzheimer's Disease, vol. 49, no. 2, pp. 493-502, 2016

Authors: Fladby, Tormod | Pålhaugen, Lene | Selnes, Per | Waterloo, Knut | Bråthen, Geir | Hessen, Erik | Almdahl, Ina Selseth | Arntzen, Kjell-Arne | Auning, Eirik | Eliassen, Carl Fredrik | Espenes, Ragna | Grambaite, Ramune | Grøntvedt, Gøril Rolfseng | Johansen, Krisztina Kunszt | Johnsen, Stein Harald | Kalheim, Lisa Flem | Kirsebom, Bjørn-Eivind | Müller, Kai Ivar | Nakling, Arne Exner | Rongve, Arvid | Sando, Sigrid Botne | Siafarikas, Nikias | Stav, Ane Løvli | Tecelao, Sandra | Timon, Santiago | Bekkelund, Svein Ivar | Aarsland, Dag

Article Type: Research Article

Abstract: While APOE ɛ 4 is the major genetic risk factor for Alzheimer’s disease (AD), amyloid dysmetabolism is an initial or early event predicting clinical disease and is an important focus for secondary intervention trials. To improve identification of cases with increased AD risk, we evaluated recruitment procedures using pathological CSF concentrations of Aβ42 (pAβ) and APOE ɛ 4 as risk markers in a multi-center study in Norway. In total, 490 subjects aged 40–80 y were included after response to advertisements and media coverage or memory clinics referrals. Controls (n  = 164) were classified as normal controls without first-degree relatives with dementia …(NC), normal controls with first-degree relatives with dementia (NCFD), or controls scoring below norms on cognitive screening. Patients (n  = 301) were classified as subjective cognitive decline or mild cognitive impairment. Subjects underwent a clinical and cognitive examination and MRI according to standardized protocols. Core biomarkers in CSF from 411 and APOE genotype from 445 subjects were obtained. Cases (both self-referrals (n  = 180) and memory clinics referrals (n  = 87)) had increased fractions of pAβ and APOE ɛ 4 frequency compared to NC. Also, NCFD had higher APOE ɛ 4 frequencies without increased fraction of pAβ compared to NC, and cases recruited from memory clinics had higher fractions of pAβ and APOE ɛ 4 frequency than self-referred. This study shows that memory clinic referrals are pAβ enriched, whereas self-referred and NCFD cases more frequently are pAβ negative but at risk (APOE ɛ 4 positive), suitable for primary intervention. Show more

Keywords: Alzheimer’s disease, amyloid, apolipoprotein E4, biomarkers, cerebrospinal fluid, mild cognitive impairment, subjective cognitive decline

DOI: 10.3233/JAD-170231

Citation: Journal of Alzheimer's Disease, vol. 60, no. 1, pp. 97-105, 2017

Authors: Motazedi, Ehsan | Cheng, Weiqiu | Thomassen, Jesper Q. | Frei, Oleksandr | Rongve, Arvid | Athanasiu, Lavinia | Bahrami, Shahram | Shadrin, Alexey | Ulstein, Ingun | Stordal, Eystein | Brækhus, Anne | Saltvedt, Ingvild | Sando, Sigrid B. | O’Connell, Kevin S. | Hindley, Guy | van der Meer, Dennis | Bergh, Sverre | Nordestgaard, Børge G. | Tybjærg-Hansen, Anne | Bråthen, Geir | Pihlstrøm, Lasse | Djurovic, Srdjan | Frikke-Schmidt, Ruth | Fladby, Tormod | Aarsland, Dag | Selbæk, Geir | Seibert, Tyler M. | Dale, Anders M. | Fan, Chun C. | Andreassen, Ole A.

Article Type: Research Article

Abstract: Background: Polygenic hazard scores (PHS) estimate age-dependent genetic risk of late-onset Alzheimer’s disease (AD), but there is limited information about the performance of PHS on real-world data where the population of interest differs from the model development population and part of the model genotypes are missing or need to be imputed. Objective: The aim of this study was to estimate age-dependent risk of late-onset AD using polygenic predictors in Nordic populations. Methods: We used Desikan PHS model, based on Cox proportional hazards assumption, to obtain age-dependent hazard scores for AD from individual genotypes in the Norwegian DemGene cohort (n  = 2,772). …We assessed the risk discrimination and calibration of Desikan model and extended it by adding new genotype markers (the Desikan Nordic model). Finally, we evaluated both Desikan and Desikan Nordic models in two independent Danish cohorts: The Copenhagen City Heart Study (CCHS) cohort (n  = 7,643) and The Copenhagen General Population Study (CGPS) cohort (n  = 10,886). Results: We showed a robust prediction efficiency of Desikan model in stratifying AD risk groups in Nordic populations, even when some of the model SNPs were missing or imputed. We attempted to improve Desikan PHS model by adding new SNPs to it, but we still achieved similar risk discrimination and calibration with the extended model. Conclusion: PHS modeling has the potential to guide the timing of treatment initiation based on individual risk profiles and can help enrich clinical trials with people at high risk to AD in Nordic populations. Show more

Keywords: Age at onset, Alzheimer’s disease, Nordic ancestry, polygenic hazard score

DOI: 10.3233/JAD-220174

Citation: Journal of Alzheimer's Disease, vol. 88, no. 4, pp. 1533-1544, 2022